<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092020000300176</article-id>
<article-id pub-id-type="doi">10.35366/94897</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Fracción de eyección del ventrículo izquierdo y proteína C reactiva como pronóstico de mortalidad en cardiomiopatía séptica]]></article-title>
<article-title xml:lang="en"><![CDATA[Low filling pressures and decreased ejection fraction and C-reactive protein as a prognosis of mortality in septic cardiomyopathy]]></article-title>
<article-title xml:lang="pt"><![CDATA[FEVE e proteína C reactiva como previsão de mortalidade na cardiomiopatia séptica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Larrazabal]]></surname>
<given-names><![CDATA[Elvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Rodríguez]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cortés Munguía]]></surname>
<given-names><![CDATA[José Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Padilla Sandoval]]></surname>
<given-names><![CDATA[Edilberto Aarón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General «La Villa»  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General «La Villa»  Unidad de Cuidados Intensivos]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital General Balbuena Unidad de Cuidados Intensivos ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>34</volume>
<numero>3</numero>
<fpage>176</fpage>
<lpage>183</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092020000300176&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092020000300176&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092020000300176&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La sepsis es una afección que comúnmente se encuentra en la Unidad de Cuidados Intensivos (UCI) y presenta costos significativos, tanto económicos como humanos. La miocardiopatía séptica es un fenómeno conocido pero poco diagnosticado, la cual se desarrolla en 60% de los pacientes y se caracteriza por la presencia de dilatación del ventrículo izquierdo con presiones de llenado normales o bajas y disminución de la fracción de eyección del ventrículo izquierdo (FEVI). Es reversible y se normaliza dentro de los siete a 10 días del inicio, teniendo un impacto negativo en la supervivencia del paciente.  Objetivo:  Evaluar si la relación de la FEVI y la proteína C reactiva funcionan como pronóstico de mortalidad en pacientes con cardiomiopatía séptica.  Material y métodos:  Se realizó un estudio observacional, descriptivo, prospectivo y multicéntrico en pacientes con sepsis que hayan sido ingresados a la UCI a las 24 horas y a los siete días de estancia. Se analizaron variables como proteína C reactiva (PCR), FEVI, edad y género. La finalidad fue correlacionar si la disminución de la FEVI y niveles de elevados de proteína C reactiva son útiles para el pronóstico de cardiomiopatía séptica.  Resultados:  Se estudiaron a 76 pacientes; de este número, se incluyeron 53 pacientes, excluyendo 14, quienes fallecieron, y nueve, que se dieron de alta antes de los siete días. La distribución por género fue de 61.3% para hombres y de 38.7% para mujeres; la edad promedio fue de 48 años. Se observó que en aquellos pacientes con una FEVI a las 24 horas &#8805; 49.5% se mostró una mayor supervivencia a corto plazo (siete días). Hubo una correlación moderada entre la PCR a las 24 horas y FEVI a las 24 horas. Los valores a los siete días mostraron una correlación alta, y finalmente, los valores de FEVI mostraron la mayor correlación con los valores de PCR, ambos a los siete días.  Conclusiones:  Durante el estudio, se observó que el valor promedio de PCR a las 24 horas es moderadamente significativo, con una especificidad de 50% para pronóstico de mortalidad. Una FEVI de &lt; 49.5% tiene una sensibilidad de 89.5% y una especificidad de 85.7% para el pronóstico de mortalidad a los siete días, con un coeficiente de determinación entre PCR y FEVI a los siete días de 57%, lo que indica que el aumento de la PCR explica la disminución de la FEVI a los siete días.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Sepsis is a common condition found in the Intensive Care Unit (ICU) with significant costs, both economic and human. Septic cardiomyopathy is a known but poorly diagnosed phenomenon, which develops in 60% of patients and is characterized by the presence of left ventricular dilation with normal or low filling pressures and decreased ejection fraction (LVEF), It is reversible, and normalizes within seven to 10 days of onset, having a negative impact on patient survival.  Objective:  To evaluate the relationship of LVEF and C-Reactive Protein as a prognosis of mortality in septic cardiomyopathy.  Material and methods:  A prospective descriptive, multicenter observational study was conducted in septic patients admitted to the ICU at 24 hours and seven days after their stay. Variables such as C-reactive protein (CRP), left ventricular ejection fraction (LVEF), age and gender were analyzed. The purpose was to correlate that the decrease in LVEF and elevated levels of C-reactive protein are useful for the prognosis of septic cardiomyopathy.  Results:  76 patients were studied, a total of 53 patients were included, excluding 14 who died and 9 who were discharged before seven days. The distribution by gender was 61.3% men and 38.7% women, the average age was 48 years. It is observed that depending on the time, those patients with a LVEF at 24 hours &#8805; 49.5% show greater short-term survival (seven days). There was a moderate correlation between CRP at 24 hours and LVEF at 24 hours. The values at seven days show a high correlation and finally the LVEF values show the highest correlation with the CRP values, both at seven days.  Conclusions:  During the study it was observed that the average value of CRP at 24 hours is moderately significant with a specificity of 50% for mortality prognosis. An LVEF of &lt; 49.5% has a sensitivity of 89.5% and a specificity of 85.7% for seven-day mortality prognosis, with a coefficient of determination between CRP and LVEF at seven days of 57% indicating that the increase in CRP explains the decrease in LVEF at seven days.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  A sepse é uma condição comum encontrada na Unidade de Terapia Intensiva (UTI) com custos significativos, tanto financeiros quanto humanos. A cardiomiopatia séptica é um fenômeno bem conhecido, mas pouco diagnosticado, que se desenvolve em 60% dos pacientes e é caracterizada pela presença de dilatação do ventrículo esquerdo com pressões de enchimento normais ou baixas e diminuição da fração de ejeção (FEVE). É reversível e normaliza dentro de 7 a 10 dias após o início, tendo um impacto negativo na sobrevida do paciente.  Objetivo:  Avaliar a relação da FEVE e da proteína C reativa como prognóstico de mortalidade na cardiomiopatia séptica.  Material e métodos:  Estudo prospectivo, multicêntrico, observacional, descritivo, realizado em pacientes sépticos internados na UTI às 24 horas e aos 7 dias de internação. Foram analisadas variáveis &#8203;&#8203;como proteína C-reativa (PCR), fração de ejeção do ventrículo esquerdo (FEVE), idade e sexo. O objetivo foi correlacionar que a diminuição da FEVE e os níveis elevados de proteína C-reativa são úteis para o prognóstico da cardiomiopatia séptica.  Resultados:  Foram estudados 76 pacientes, um total de 53 pacientes foram incluídos, excluindo 14 que morreram e 9 que receberam alta antes de 7 dias. A distribuição por gênero foi de 61.3% homens e 38.7% mulheres, com idade média de 48 anos. Observa-se que, em função do tempo, aqueles pacientes com FEVE de 24 horas &#8805; 49.5% apresentam maior sobrevida no curto prazo (7 dias). Houve uma correlação moderada entre a PCR de 24 horas e a FEVE de 24 horas. Os valores em 7 dias mostram uma alta correlação e, finalmente, os valores da FEVE mostram a maior correlação com os valores de PCR, ambos em 7 dias.  Conclusões:  Durante o estudo, observou-se que o valor médio da PCR em 24 horas é moderadamente significativo, com especificidade de 50% para prognóstico de mortalidade. A FEVE &lt; 49.5% apresenta sensibilidade de 89.5% e especificidade de 85.7% para prognóstico de mortalidade aos 7 dias, com coeficiente de determinação entre PCR e FEVE aos 7 dias de 57%, indicando que o aumento da PCR explica a diminuição da FEVE aos 7 dias.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sepsis]]></kwd>
<kwd lng="es"><![CDATA[miocardiopatía séptica]]></kwd>
<kwd lng="es"><![CDATA[FEVI]]></kwd>
<kwd lng="es"><![CDATA[proteína C reactiva]]></kwd>
<kwd lng="en"><![CDATA[Sepsis]]></kwd>
<kwd lng="en"><![CDATA[septic cardiomyopathy]]></kwd>
<kwd lng="en"><![CDATA[LVEF]]></kwd>
<kwd lng="en"><![CDATA[C-reactive protein]]></kwd>
<kwd lng="pt"><![CDATA[Sepse]]></kwd>
<kwd lng="pt"><![CDATA[cardiomiopatia séptica]]></kwd>
<kwd lng="pt"><![CDATA[FEVE]]></kwd>
<kwd lng="pt"><![CDATA[proteína C reativa]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kakihana]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakahara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis-induced myocardial dysfunction: pathophysiology and management. Review article]]></article-title>
<source><![CDATA[Journal of Intensive Care]]></source>
<year>2016</year>
<volume>4</volume>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsolaki]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Makris]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mantzarlis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zakynthinos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis-induced cardiomyopathy: oxidative implications in the initiation and resolution of the damage. Review article. Hindawi?]]></article-title>
<source><![CDATA[Oxidative Medicine and Cellular Longevity]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ehrman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Favot]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sherwin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Abidov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2018</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>112</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Proteína C reactiva como marcador de inflamación]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Española de Farmacéuticos Analistas D.L]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sproston]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Ashworth]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of C-reactive protein at sites of inflammation and infection. Review article]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>754</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rincón]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Ecocardiografía clínica en el paciente crítico]]></source>
<year>2014</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[ZarPra Ediciones]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treacher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septic cardiomyopathy: pathophysiology and prognosis]]></article-title>
<source><![CDATA[Signa Vitae]]></source>
<year>2017</year>
<volume>13</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>40-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paonessa]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Steinhaus]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Celi]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperdynamic left ventricular ejection fraction in the intensive care unit. Research Article]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>288</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[De Andrade]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[De Andrade]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Lagoeiro]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From echocardiographic evaluation to biomarkers measurement: the role of myocardial dysfunction in mortality associated with sepsis. Review article]]></article-title>
<source><![CDATA[Int J Cardiovasc Sci]]></source>
<year>2018</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>643-51</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rolando]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Avid]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Del Pozo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Risso]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of ventricular diastolic dysfunction in patients with severe sepsis and septic shock. Original article]]></article-title>
<source><![CDATA[Rev Bras Ter Intensiva]]></source>
<year>2015</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>333-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sitges]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía práctica de ecocardiografía]]></source>
<year>2012</year>
<page-range>440</page-range><publisher-loc><![CDATA[Barcelona Spain ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellikka]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[She]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Holly]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Varadarajan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variability in ejection fraction measured by echocardiography, gated single-photon emission computed tomography, and cardiac magnetic resonance in patients with coronary artery disease and left ventricular dysfunction]]></article-title>
<source><![CDATA[JAMA Network Open]]></source>
<year>2018</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors and outcomes of sepsis-induced myocardial dysfunction and stress-induced cardiomyopathy in sepsis or septic shock? A comparative retrospective study]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2018</year>
<volume>97</volume>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gewurz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Molde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fiedel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proteína C reactiva y la respuesta de fase aguda]]></article-title>
<source><![CDATA[Adv Intern Med]]></source>
<year>1982</year>
<volume>27</volume>
<page-range>345-72</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez-Amorocho]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Patiño-Cuervo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proteína C reactiva ultrasensible (PCR-us) como marcador de riesgo de enfermedad cardiovascular]]></article-title>
<source><![CDATA[Medicina &amp; Laboratorio]]></source>
<year>2008</year>
<volume>14</volume>
<numero>9-10</numero>
<issue>9-10</issue>
<page-range>457-78</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capelini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Durazo]]></surname>
<given-names><![CDATA[QF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La proteína C reactiva ultrasensible, un marcador de riesgo cardiovascular]]></article-title>
<source><![CDATA[Rev Mex Patol Clin]]></source>
<year>2008</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>55-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
